Exploiting apoptosis pathways for the treatment of pediatric cancers

Simone Fulda1

  • 1University Children's Hospital, Ulm, Germany. simone.fulda@uniklinik-ulm.de

Pediatric Blood & Cancer
|January 17, 2009
PubMed

Insights

Childhood cancers often resist programmed cell death, a key factor in treatment failure. Targeting apoptosis pathways offers a promising strategy for developing novel molecular therapies against pediatric malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Resistance to apoptosis (programmed cell death) is a hallmark of human cancers, including pediatric malignancies.
  • Evasion of apoptosis is a primary mechanism of resistance to conventional anti-cancer therapies like chemotherapy and radiotherapy.
  • Understanding apoptosis pathways is crucial for overcoming treatment resistance in cancer.

Purpose of the Study:

  • To highlight the significance of apoptosis resistance in pediatric cancers.
  • To review the identification of key molecular targets within apoptosis pathways in pediatric tumors.
  • To discuss the potential of molecularly targeted therapies for childhood cancers.

Main Methods:

  • Dissection of apoptosis pathways in pediatric tumors over the last two decades.
  • Identification of key molecules involved in apoptosis as potential drug targets.
  • Review of current strategies for developing targeted therapies based on apoptosis components.

Main Results:

  • Numerous key molecules regulating apoptosis have been identified in pediatric tumors.
  • These identified molecules represent viable targets for novel drug discovery.
  • The understanding of apoptosis pathways has advanced significantly in pediatric oncology.

Conclusions:

  • Targeting apoptosis pathways is a rational approach for developing new anti-cancer drugs.
  • Molecularly targeted therapies hold promise for more effective treatment of childhood cancers.
  • Exploiting the apoptotic cascade can lead to improved outcomes for pediatric cancer patients.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...